NetworkNewsBreaks – VistaGen Therapeutics (NASDA
Post# of 130
(Total Views: 249)
Posted On: 09/30/2020 3:44:27 PM
NetworkNewsBreaks – VistaGen Therapeutics (NASDAQ: VTGN) CEO Addresses ‘Multi-Pronged Approach’ to Growing Problem of Workplace Stress and Anxiety
VistaGen Therapeutics’ (NASDAQ: VTGN) CEO Shawn Singh authored a recent article for Business.com regarding the COVID-19 pandemic and resulting stress and anxiety impacts to the workplace. In the piece, Singh indicates that stress and anxiety, often driven by job-related issues, when left unchecked can rise to the level of an anxiety disorder with negative consequences for physical health, mental well-being, productivity and career opportunities. The global pandemic has exacerbated this largely unaddressed and widespread mental health problem in the workplace, markedly reflecting in increased prescriptions for antidepressant and anti-anxiety medications, many associated with significant side effects and safety concerns. “To adequately address the growing problem of workplace stress and anxiety both during and after the COVID-19 pandemic – and the physical and mental health consequences associated with it – a multi-pronged approach is needed,” states Singh in the article. “This approach should include the provision of additional mental/emotional health support from employers in the form of employee assistance programs (‘EAPs’), as well as novel approaches to psychotherapy and fundamentally different medications by mental health professionals.”ed gross proceeds of approximately $12.6 million before deducting underwriting discounts and commissions and other estimated expenses. The company has announced that it intends to use the net proceeds from the offering for sales and marketing, growth capital, research and development; any remainder would be used for working capital. Psagot Investment House, an Israeli investment firm and the country’s largest pension fund manager, was the lead investor in the offering.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
VistaGen Therapeutics’ (NASDAQ: VTGN) CEO Shawn Singh authored a recent article for Business.com regarding the COVID-19 pandemic and resulting stress and anxiety impacts to the workplace. In the piece, Singh indicates that stress and anxiety, often driven by job-related issues, when left unchecked can rise to the level of an anxiety disorder with negative consequences for physical health, mental well-being, productivity and career opportunities. The global pandemic has exacerbated this largely unaddressed and widespread mental health problem in the workplace, markedly reflecting in increased prescriptions for antidepressant and anti-anxiety medications, many associated with significant side effects and safety concerns. “To adequately address the growing problem of workplace stress and anxiety both during and after the COVID-19 pandemic – and the physical and mental health consequences associated with it – a multi-pronged approach is needed,” states Singh in the article. “This approach should include the provision of additional mental/emotional health support from employers in the form of employee assistance programs (‘EAPs’), as well as novel approaches to psychotherapy and fundamentally different medications by mental health professionals.”ed gross proceeds of approximately $12.6 million before deducting underwriting discounts and commissions and other estimated expenses. The company has announced that it intends to use the net proceeds from the offering for sales and marketing, growth capital, research and development; any remainder would be used for working capital. Psagot Investment House, an Israeli investment firm and the country’s largest pension fund manager, was the lead investor in the offering.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)